Bureau of Oceans and International Environmental and Scientific Affairs

TFF Pharmaceuticals Announces Publication of Data Demonstrating Feasibility of Intranasal Delivery of Monoclonal Antibodies with Thin Film Freezing

Retrieved on: 
Wednesday, November 8, 2023
Freezing, AptarGroup, Hook effect, Therapy, Government, UDS, Bureau of Oceans and International Environmental and Scientific Affairs, BioRxiv, Research, Developmental toxicity, TFF, Pharmaceutical industry

FORT WORTH, Texas, Nov. 08, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the publication of research demonstrating the feasibility of intranasal delivery of monoclonal antibodies (mAbs) using the Company’s proprietary Thin Film Freezing technology.

Key Points: 
  • FORT WORTH, Texas, Nov. 08, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the publication of research demonstrating the feasibility of intranasal delivery of monoclonal antibodies (mAbs) using the Company’s proprietary Thin Film Freezing technology.
  • The paper, entitled “Feasibility of Intranasal Delivery of Thin-film Freeze-dried Monoclonal Antibodies”, was first published on October 24, 2023, by bioRxiv and can be found here .
  • Maintaining low molecular weight for droplet/particle size distribution is considered to be a critical attribute for effective delivery of intranasal liquid products.
  • “We are pleased with the results of this research, which provide further evidence that Thin Film Freezing can be applied across a board range of antibody-based drug candidates for intranasal delivery,” said Dr. Harlan Weisman, Chief Executive Officer of TFF Pharmaceuticals.

SolvEat's Botanical Composition Supports Blood Sugar Balance in A Chocolate Delight

Retrieved on: 
Tuesday, November 7, 2023
Partial, Herbal medicine, TEL, MD, Crataegus, Bureau of Oceans and International Environmental and Scientific Affairs, News, Chocolate, Prediabetes, Clinical trial, Coptis, School, B cell, CBO, Diagnosis, Nudelman, Glucose, Insulin, Dietary supplement, Medicinal plants, Rehmannia

TEL AVIV, Israel, Nov. 7, 2023 /PRNewswire/ -- Food-tech start-up SolvEat brings research-supported botanical compositions to the functional foods space. The bioactive solution is designed to help maintain healthy blood sugar levels when used as part of a regular diet. SolvEat collaborated with a chocolate company to develop a chocolate bar prototype as a first proof of concept. SolvEat will introduce the new composition at Fi Europe in Frankfurt, booth no. 3.0L151

Key Points: 
  • The bioactive solution is designed to help maintain healthy blood sugar levels when used as part of a regular diet.
  • SolvEat collaborated with a chocolate company to develop a chocolate bar prototype as a first proof of concept.
  • "The botanical extracts in our solution work synergistically to balance blood sugar levels through supporting various organs in the body and that's why each is essential to the efficacy of the formula."
  • The company successfully integrated its botanical composition in an indulgent yet guilt-free chocolate bar.

RS BioTherapeutics Promotes Michelle L. Shuffett, MD to Chief Medical Officer

Retrieved on: 
Tuesday, October 31, 2023
Knowledge, University, Children's Hospital Los Angeles, London, Medicine, Barts and The London School of Medicine and Dentistry, Born This Way Foundation, MD, TEC, Bureau of Oceans and International Environmental and Scientific Affairs, Organization, Health, Research, IPF, Senior, RS, Boehringer Ingelheim, Everyday Health, Idiopathic disease, UCLA Mattel Children's Hospital, NIH, Patient, Hospital, COPD, Idiopathic pulmonary fibrosis, Child, Pharmaceutical industry, Nursing, Economics

CUMBERLAND, Md., Oct. 31, 2023 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation, is pleased to announce that it has appointed Michelle L. Shuffett, MD as its Chief Medical Officer.

Key Points: 
  • CUMBERLAND, Md., Oct. 31, 2023 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation, is pleased to announce that it has appointed Michelle L. Shuffett, MD as its Chief Medical Officer.
  • Commenting on the promotion of Dr. Shuffett to Chief Medical Officer, Dean Hart, Chief Executive Officer of RS BioTherapeutics said, “Michelle has been a tremendous addition to our leadership team.
  • Michelle will Chair the TEC and that group will help guide the development of RSBT-001.”
    Commenting on her appointment, Dr. Shuffett said, “I’m thrilled to continue working with the incredible leadership team at RS BioTherapeutics in this new role.
  • Dr. Shuffett has also served in senior roles at several organizations including Synapse Medical Communications, Everyday Health, Columbia Care, and Radicle Science.

ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide

Retrieved on: 
Wednesday, November 1, 2023
Vitamins, Supplements, Other Retail, Marketing, Fitness & Nutrition, Communications, Specialty, Health, Retail, Influencer, OBGYN, Nicotinamide adenine dinucleotide, Ageing, NSF International, Major League Baseball, Senior ice hockey, Depression, NAD, Internet, Physician, ChromaDex, National Hockey League, Host, Bureau of Oceans and International Environmental and Scientific Affairs, Research, Multimedia, Senior, MLB, USADA, Nobel Prize, NHL, Safety, NR, Dietary supplement, Medical device, Nicotinamide riboside, RD, Habit

ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) research and healthy aging, launches its clinical strength Tru Niagen® Pro 1,000mg , featuring 1,000mg of Niagen® (patented Nicotinamide Riboside or NR), one of the most efficient and superior quality NAD+ precursors on the market, to consumers nationwide.

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) research and healthy aging, launches its clinical strength Tru Niagen® Pro 1,000mg , featuring 1,000mg of Niagen® (patented Nicotinamide Riboside or NR), one of the most efficient and superior quality NAD+ precursors on the market, to consumers nationwide.
  • With 1,000mg of Niagen used in over 50% of published clinical studies, this serving is redefining research for NAD+ related health outcomes.
  • “As a pioneer of NAD+ research, our team works with esteemed investigators across the globe to uncover the full potential of NAD+.
  • Tru Niagen Pro 1,000mg was unveiled to a select group of Key Opinion Leaders (KOLs), physicians, influencers and celebrities at the Tru Niagen Wellness Retreat in Malibu last week.

National Sleep Foundation Study Results Show Drowsy Driving Begins During Teen Years

Retrieved on: 
Thursday, November 2, 2023
Science, Research, Social media, Education, Governors Highway Safety Association, Health, National Alliance, Somnolence, National Sleep Foundation, Fatality, Bureau of Oceans and International Environmental and Scientific Affairs, News, Doctor of Philosophy, Blinking, Samsung Health, General Motors, AAA Foundation for Traffic Safety, Risk, Road traffic safety, Sleep, Safety, NSF, Birth control, Pharmaceutical industry, Road, Mobile phone, Hotel

WASHINGTON, Nov. 2, 2023 /PRNewswire/ -- Today, the National Sleep Foundation (NSF) released results of a new survey of American teens highlighting their attitudes and behaviors about drowsy driving. Teens reported driving drowsy at high rates, especially considering their status as new drivers. Teens also said school and job commitments were the top factors keeping them from getting the sleep they need to drive alert. A corresponding NSF survey of US adult drivers showed similar results about the top contributors to their drowsiness behind the wheel, but with greater frequency of driving while drowsy. Teens and adults called drowsy driving "highly-risky."

Key Points: 
  • New survey of teen drivers shows attitudes and actions about impaired driving, implications for sleep health
    WASHINGTON, Nov. 2, 2023 /PRNewswire/ -- Today, the National Sleep Foundation (NSF) released results of a new survey of American teens highlighting their attitudes and behaviors about drowsy driving.
  • National Sleep Foundation's survey results show drowsy driving begins during the teen years.
  • National Sleep Foundation's 2023 Drowsy Driving Survey was fielded as part of Drowsy Driving Prevention Week® , NSF's annual campaign to help Americans get the sleep they need and reduce the number of drivers who get behind the wheel while sleep deprived.
  • Overall, teens know the risks of drowsy driving, but don't think it's as risky as other forms of impaired driving," said Joseph Dzierzewski, PhD, Vice President, Research and Scientific Affairs, National Sleep Foundation.

ICON's World Children's Day; access and inclusion for every child, upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, October 30, 2023
Penta, Children's Day, FDA, Maternal health, DO, Food, ICON, Therapy, Center for Drug Evaluation and Research, MD, Bureau of Oceans and International Environmental and Scientific Affairs, Rights, Doctor of Philosophy, Drug development, UN General Assembly Resolution 60/147, Food and Drug Administration, Caregiver, University of Padua, Convention, University, Declaration of the Rights of the Child, Patient, UN, MS, Pharmaceutical industry, Research, Child

TORONTO, Oct. 30, 2023 /PRNewswire-PRWeb/ -- ICON's Centre for Paediatric Clinical Development invites you to celebrate World Children's Day virtually with us on November 13, 2023. World Children's Day is recognised as an international coming together to advocate for, promote, and celebrate the rights and welfare of children and create dialogue and action plans to build a better world for children. First established in 1954, it also commemorates the day when the UN General Assembly adopted the Declaration of the Rights of the Child in 1959 and when the UN General Assembly adopted the Convention on the Rights of the Child in 1989.

Key Points: 
  • Attendees will learn about increasing awareness of the needs and effort behind providing access to safe and accurate dosage forms of medicines for every child.
  • The featured speakers will discuss how drug development can be expedited for children and their families to provide access to adapted medicines and innovative medicines.
  • TORONTO, Oct. 30, 2023 /PRNewswire-PRWeb/ -- ICON's Centre for Paediatric Clinical Development invites you to celebrate World Children's Day virtually with us on November 13, 2023.
  • For more information, or to register for this event, visit ICON's World Children's Day .

Pfizer Holds MERA Vaccines Summit to Discuss the Impact of Vaccines on Controlling Diseases in the Region

Retrieved on: 
Monday, October 30, 2023
Urinary tract infection, Hajj, Pregnancy, International, Infection, Vaccine, Literature, Physician, Bureau of Oceans and International Environmental and Scientific Affairs, Vaccination, MERA, Disease, COVID-19, Risk, Public, Hospital, Patient, Pharmaceutical industry, Pfizer

The MERA Vaccines Summit brought together more than 100 physicians and healthcare professionals to Dubai to discuss a range of communicable diseases.

Key Points: 
  • The MERA Vaccines Summit brought together more than 100 physicians and healthcare professionals to Dubai to discuss a range of communicable diseases.
  • The summit educated healthcare professionals with the latest literature on vaccines, and its impact to the region's population.
  • Vaccines are critical to reducing disease burden and countering new variants of diseases, especially for those at most risk of hospitalization.
  • DUBAI, UAE, Oct. 30, 2023 /PRNewswire/ -- Pfizer Middle East, Russia and Africa (MERA) hosted the MERA Vaccines Summit, welcoming more than 100 physicians and healthcare professionals from around the region to Dubai, United Arab Emirates.

Pfizer Holds MERA Vaccines Summit to Discuss the Impact of Vaccines on Controlling Diseases in the Region

Retrieved on: 
Monday, October 30, 2023
Urinary tract infection, Hajj, Pregnancy, International, Infection, Vaccine, Literature, Physician, Bureau of Oceans and International Environmental and Scientific Affairs, Vaccination, MERA, Disease, COVID-19, Risk, Public, Hospital, Patient, Pharmaceutical industry, Pfizer

The MERA Vaccines Summit brought together more than 100 physicians and healthcare professionals to Dubai to discuss a range of communicable diseases.

Key Points: 
  • The MERA Vaccines Summit brought together more than 100 physicians and healthcare professionals to Dubai to discuss a range of communicable diseases.
  • The summit educated healthcare professionals with the latest literature on vaccines, and its impact to the region's population.
  • Vaccines are critical to reducing disease burden and countering new variants of diseases, especially for those at most risk of hospitalization.
  • DUBAI, UAE, Oct. 30, 2023 /PRNewswire/ -- Pfizer Middle East, Russia and Africa (MERA) hosted the MERA Vaccines Summit, welcoming more than 100 physicians and healthcare professionals from around the region to Dubai, United Arab Emirates.

Clario's Precision Motion Opal® technology powers University of Oxford breakthrough in Parkinson's Disease

Retrieved on: 
Friday, October 27, 2023
Digital, PSP, Parallel Walk Test, Clario Tech, Gait, PD, Medicine, Bureau of Oceans and International Environmental and Scientific Affairs, Neurology, APDM, University, HIV disease progression rates, Parkinson's disease, Machine learning, Algorithm, University of Oxford, Collection, Movement, Patient, Disability studies, Associate, Pharmaceutical industry, Medical imaging, Neuroscience, Parkinsonism, Disease, Doctor of Philosophy

Clario's Precision Motion Opal® wearable sensor technology detects early Parkinson's disease (PD) progression in a University of Oxford study funded by UCB Pharma.

Key Points: 
  • Clario's Precision Motion Opal® wearable sensor technology detects early Parkinson's disease (PD) progression in a University of Oxford study funded by UCB Pharma.
  • Earlier detection supported by state-of-the-art sensor technology and machine learning is a promising discovery to aid in the expedited development of effective PD treatments.
  • Importantly, they found that the wearable technology detected disease progression in a significantly shorter timeframe than the traditional method.
  • "Time is crucial in clinical trials," said Professor Antoniades, Associate Professor of Neuroscience, Clinical Neurology at the University of Oxford.

Clario's Precision Motion Opal® technology powers University of Oxford breakthrough in Parkinson's Disease

Retrieved on: 
Friday, October 27, 2023
Digital, PSP, Parallel Walk Test, Clario Tech, Gait, PD, Medicine, Bureau of Oceans and International Environmental and Scientific Affairs, Neurology, APDM, University, HIV disease progression rates, Parkinson's disease, Machine learning, Algorithm, University of Oxford, Collection, Movement, Patient, Disability studies, Associate, Pharmaceutical industry, Medical imaging, Neuroscience, Parkinsonism, Disease, Doctor of Philosophy

Clario's Precision Motion Opal® wearable sensor technology detects early Parkinson's disease (PD) progression in a University of Oxford study funded by UCB Pharma.

Key Points: 
  • Clario's Precision Motion Opal® wearable sensor technology detects early Parkinson's disease (PD) progression in a University of Oxford study funded by UCB Pharma.
  • Earlier detection supported by state-of-the-art sensor technology and machine learning is a promising discovery to aid in the expedited development of effective PD treatments.
  • Importantly, they found that the wearable technology detected disease progression in a significantly shorter timeframe than the traditional method.
  • "Time is crucial in clinical trials," said Professor Antoniades, Associate Professor of Neuroscience, Clinical Neurology at the University of Oxford.